• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Graybug Vision Inc.

    1/26/24 4:15:05 PM ET
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRAY alert in real time by email
    SC 13G 1 ea192128-13gsoleus_calci.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    CalciMedica, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    38942Q202

    (CUSIP Number)

     

    January 23, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 38942Q202

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital Master Fund, L.P.
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    783,904 (1)(2)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    783,904 (1)(2)
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    783,904 (1)(2)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.4% (3)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    FI

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.
       
    (2) Includes presently exercisable warrants to purchase up to 391,952 shares of the common stock of the Issuer (“Common Stock”).

     

    (3) This percentage is calculated based upon 10,257,077 shares of Common Stock outstanding as of the close of business on January 23, 2024, after giving effect to the initial closing of the transaction contemplated by the Securities Purchase Agreement dated as of January 19, 2024 among the Issuer and the purchasers identified on the signature pages thereto (the “Financing”).

     

    2

     

     

    CUSIP No. 38942Q202

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    783,904 (1)(2)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    783,904 (1)(2)
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    783,904 (1)(2)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.4% (3)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.
       
    (2) Includes presently exercisable warrants to purchase up to 391,952 shares of Common Stock.

     

    (3) This percentage is calculated based upon 10,257,077 shares of Common Stock outstanding as of the close of business on January 23, 2024 after giving effect to the initial closing of the Financing.

     

    3

     

     

    CUSIP No. 38942Q202

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital Group, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    783,904 (1)(2)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    783,904 (1)(2)
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    783,904 (1)(2)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.4% (3)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.
       
    (2) Includes presently exercisable warrants to purchase up to 391,952 shares of Common Stock.

     

    (3) This percentage is calculated based upon 10,257,077 shares of Common Stock outstanding as of the close of business on January 23, 2024 after giving effect to the initial closing of the Financing.

     

    4

     

     

    CUSIP No. 38942Q202

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Guy Levy
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    783,904 (1)(2)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    783,904 (1)(2)
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    783,904 (1)(2)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    7.4% (3)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.
       
    (2) Includes presently exercisable warrants to purchase up to 391,952 shares of Common Stock.

     

    (3) This percentage is calculated based upon 10,257,077 shares of Common Stock outstanding as of the close of business on January 23, 2024 after giving effect to the initial closing of the Financing.

     

    5

     

     

    Item 1.

     

      (a) Name of Issuer
        CalciMedica, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices
        505 Coast Boulevard South, Suite 307
    La Jolla, CA 92037

     

    Item 2.

     

      (a) Name of Person(s) Filing
       

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence
       

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c) Citizenship
       

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC - Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities
        Common Stock, $0.0001 par value per share

     

      (e) CUSIP Number
        38942Q202

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    6

     

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    Master Fund beneficially owned, as of the close of business on January 23, 2024, an aggregate of 783,904 shares of the common stock of the Issuer, including 391,952 shares of common stock issuable upon the exercise of presently exercisable warrants. As the general partner of Master Fund, Soleus Capital may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, SCG may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of SCG, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital or SCG is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification
     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 26, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:  
       
    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    8

     

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: January 26, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: January 26, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    9

     

    Get the next $GRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRAY
    SEC Filings

    See more
    • Graybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CalciMedica, Inc. (0001534133) (Filer)

      2/13/24 5:30:00 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Graybug Vision Inc.

      EFFECT - CalciMedica, Inc. (0001534133) (Filer)

      2/12/24 12:15:11 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Graybug Vision Inc.

      S-3 - CalciMedica, Inc. (0001534133) (Filer)

      1/31/24 5:12:29 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Financials

    Live finance-specific insights

    See more
    • Graybug and CalciMedica Enter into Definitive Merger Agreement

      – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi

      11/21/22 6:52:03 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

      REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) ("Graybug" or the "Company"), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due

      11/10/22 4:58:58 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

      BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, d

      8/11/22 7:30:00 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roberts Eric W was granted 91,086 shares, increasing direct ownership by 449% to 111,373 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      2/6/24 5:34:17 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:32 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:34 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graybug Vision downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Graybug Vision from Outperform to Market Perform and set a new price target of $5.00 from $23.00 previously

      5/13/21 7:17:20 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision downgraded by Needham

      Needham downgraded Graybug Vision from Buy to Hold

      5/13/21 6:13:16 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Graybug Vision with a new price target

      SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously

      3/15/21 8:09:07 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Announces Name and Trading Symbol Change

      REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica). About GraybugGraybug is a clinical-stage biopharmaceutical company focused on developing transform

      3/20/23 1:22:24 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug and CalciMedica Enter into Definitive Merger Agreement

      – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY) (Graybug) and CalciMedi

      11/21/22 6:52:03 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Appoints Dirk Sauer to Board of Directors

      BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies. Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Bo

      4/13/22 4:05:00 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team

      REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of Bettina Maunz as Chief People Officer. In addition to building and leading the human resources function for Graybug Vision, Ms. Maunz will serve as Head of Communications and be a member of the company’s executive team. “We are delighted for Bettina to join Graybug as Chief People Officer. Her leadership, culture and communications experience will be important assets to our team,” said Frederic Guera

      2/1/21 7:30:00 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:32 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      1/25/24 8:00:34 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wilson Robert N bought $1,670 worth of shares (506 units at $3.30), increasing direct ownership by 0.28% to 182,161 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      12/13/23 8:45:28 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)

      SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)

      2/8/24 5:55:57 PM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      2/8/24 10:08:18 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      2/7/24 11:14:29 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care